

CLOVER NEXT®

EASYAL

ACIDO IALURONICO

A CUTTING-EDGE THERAPY FOR JOINT HEALTH

In rheumatic and degenerative joint diseases, there is a degradation of the concentration and molecular weight of hyaluronic acid, resulting in a reduction in the viscosity of synovial fluid.
This leads to deterioration of joint function and the onset of pain.

The intra-articular administration of hyaluronic acid helps restore the viscoelasticity of the synovial fluid, promoting a significant improvement in joint mobility and a reduction in pain and the inflammatory response.

EASYAL is a highly purified sodium hyaluronate-based product with marked viscoelastic properties and a molecular weight ranging from 1,000 to 1,500 KDaltons.
It is available in two versions:

- 40 mg / 2 ml (2%)
- 80 mg / 4 ml (2%)

Sodium hyaluronate is a key component of synovial fluid, responsible for its viscoelastic characteristics.
The sodium hyaluronate in EASYAL is obtained through fermentation followed by purification.
The product is supplied in ready-to-use glass syringes in two different formulations: EASYAL2 and EASYAL4.

The EASYAL2 40 mg/2 ml protocol involves a cycle of three weekly injections, helping to reduce pain and swelling while restoring joint function.

The EASYAL4 80 mg/4 ml protocol involves a single injection.

MOST COMMONLY AFFECTED JOINTS:

- SHOULDER
- HAND
- HIP
- KNEE
- FOOT



METHOD OF USE.

Aspirate any joint effusion before injecting EASYAL. Remove the syringe cap, taking care to avoid contact. Insert an appropriately sized needle (18 to 22 G) and screw it in tightly, ensuring it is securely attached to prevent leakage of the solution. Inject the solution exclusively into the synovial space, at room temperature and under aseptic conditions.

Box containing 1 single-use pre-filled syringe (one syringe contains 40 mg of hyaluronic acid in 2 ml of apyrogenic solution).
Sterilized syringes.

Box containing 1 single-use pre-filled syringe (one syringe contains 80 mg of hyaluronic acid in 2 ml of apyrogenic solution).
Sterilized syringes.

DOSAGE AND INSTRUCTIONS FOR USE

EASYAL2 (40 mg) Intra-articular injection of 2 ml of product once a week for three weeks, unless otherwise directed by your physician and depending on the patient's condition.
If additional treatment cycles are required, allow at least 6 months between cycles.
If deemed appropriate by the physician and depending on the patient's condition, multiple joints may be treated at the same time.

EASYAL4 (80 mg) Intra-articular injection of 4 ml of product in a single administration, unless otherwise directed by your physician and depending on the patient's condition.
If additional treatment cycles are required, allow at least 6 months between cycles.
If deemed appropriate by the physician and depending on the patient's condition, multiple joints may be treated at the same time.

HYALURONIC ACID is a molecule composed of linear chains of polysaccharides responsible for elasticity and energy absorption. When synovial fluid is in good condition, it contains high concentrations of hyaluronic acid.

Thanks to its water-retaining capacity, hyaluronic acid has an elastic effect that helps improve cartilage lubrication and shock-absorbing performance.
In patients affected by osteoarthritis, hyaluronic acid deteriorates, losing its elastic and viscous properties, which leads to progressive joint degeneration.



Knee joint with osteoarthritis

Knee joint after treatment with EASYAL

The treatments for this condition include:

- Systemic pharmacological therapies based on NSAIDs or analgesics;
- Non-pharmacological therapies such as muscle rehabilitation and reduction of physical stress;
- Local pharmacological therapies such as cortisone injections and intra-articular treatments with hyaluronic acid (viscosupplementation).



The diagram shows how EASYAL is effective in reducing pain after just the first injection.

After three administrations, mobility, both in terms of flexibility and extension, significantly improved.

No side effects or systemic reactions were reported.

CLOVER NEXT®

Clover Orthopedics s.r.l.
M. info@cloverorthopedics.com
W. cloverorthopedics.com

T. +39 02 457 902 31
F. +39 02 457 902 66

REVOOEN
23|06|25